4.7 Article

Early-life risk factors and incidence of rhinitis: Results from the European Community Respiratory Health Study-an international population-based cohort study

Journal

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
Volume 128, Issue 4, Pages 816-+

Publisher

MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2011.05.039

Keywords

Rhinitis; atopy; gender; pet exposure; siblings; farming lifestyle

Funding

  1. National Health and Medical Research Council of Australia
  2. Clifford Craig Medical Trust
  3. GlaxoSmithKline
  4. Belgian Science Policy Office
  5. Ministere de la Sante, Glaxo France
  6. Insitut Pneumologique d'Aquitaine
  7. Contrat de Plan Etat-Region Languedoc-Rousillon
  8. CNMATS
  9. CNMRT [90MR/10, 91AF/6]
  10. Ministre delegue de la sante
  11. RNSP, France
  12. GSF
  13. Bundesminister fur Forschung und Technologie, Bonn, Germany
  14. Ministero dell'Universita e della Ricerca Scientifica e Tecnologica
  15. CNR, Regione Veneto [381/05.93]
  16. Norwegian Research Council [101422/310]
  17. Dutch Ministry of Wellbeing, Public Health and Culture, Netherlands
  18. Ministero Sanidad y Consumo FIS [91/0016060/00E-05E, 93/0393]
  19. Hospital General de Albacete
  20. Hospital General Juan Ramon Jimenenz
  21. Consejeria de Sanidad Principado de Asturias, Spain
  22. Swedish Medical Research Council
  23. Swedish Heart Lung Foundation
  24. Swedish Association against Asthma and Allergy
  25. Swiss National Science Foundation [402628099]
  26. National Asthma Campaign
  27. British Lung Foundation
  28. Department of Health
  29. South Thames Regional Health Authority, United Kingdom
  30. United States Department of Health, Education and Welfare Public Health Service [2 S07 RR05521-28]
  31. Victorian Health Promotion Foundation and Allen Hanburys
  32. European Commission
  33. Albacete: Fondo de Investigaciones Santarias (FIS) [97/0035-01, 99/0034-01, 99/0034-02]
  34. Hospital Universitario de Albacete, Consejeria de Sanidad
  35. Antwerp: FWO (Fund for Scientific Research)-Flanders Belgium [G.0402.00]
  36. University of Antwerp, Flemish Health Ministry
  37. Barcelona: SEPAR, Public Health Service [R01 HL62633-01]
  38. Fondo de Investigaciones Santarias (FIS) [97/0035-01, 99/0034-01, 99/0034-02]
  39. CIRIT [1999SGR 00241]
  40. Red Respira ISCII
  41. Basel: Swiss National Science Foundation
  42. Swiss Federal Office for Education Science
  43. USC NIEHS Center [5P30 ES07048]
  44. Bergen: Norwegian Research Council,Norwegian Asthma & Allergy Association (NAAF)
  45. Glaxo Wellcome AS
  46. Norway Research Fund
  47. Bordeaux: Institut Pneumologique d'Aquitaine
  48. Erfurt: GSF-National Research Centre for Environment Health
  49. Deutsche Forschungsgemeinschaft (DFG) [FR 1526/1-1]
  50. Galdakao: Basque Health Department
  51. Goteborg: Swedish Heart Lung Foundation
  52. Swedish Foundation for Health Care Sciences & Allergy Research
  53. Swedish Asthma & Allergy Foundation
  54. Swedish Cancer& Allergy Foundation
  55. Grenoble: Programme Hospitalier de Recherche Clinique-DRC de Grenoble [2610]
  56. Ministry of Health, Direction de la Recherche Clinique
  57. Ministere de l'Emploi et de la Solidarite
  58. Direction Generale de la Sante
  59. CHU de Grenoble
  60. Comite des Maladies Respiratoires de l'Isere
  61. Hamburg: GSF-National Research Centre for Environment Health
  62. Ipswich
  63. Norwich: AsthmaUK(formerly known as National Asthma Campaign)
  64. Huelva: Fondo de Investigaciones Santarias (FIS) [97/0035-01, 99/0034-01, 99/0034-02]
  65. Montpellier: Programme Hospitalier de Recherche Clinique-DRC de Grenoble [2610]
  66. Direction Generale de la Sante, Aventis (France)
  67. Direction Regionale des Affaires Sanitaires et Sociales Languedoc-Roussillon
  68. Oviedo: Fondo de Investigaciones Santarias (FIS) [97/0035-01, 99/0034-01, 99/0034-02]
  69. Paris: Ministere de l'Emploi et de la Solidarite
  70. UCB-Pharma (France)
  71. Aventis (France)
  72. Glaxo France
  73. Programme Hospitalier de Recherche Clinique-DRC de Grenoble [2610]
  74. Pavia: Glaxo-SmithKline Italy
  75. Italian Ministry of University and Scientific and Technological Research (MURST)
  76. Local University
  77. Portland: American Lung Association of Oregon
  78. Northwest Health Foundation
  79. Collins Foundation
  80. Merck Pharmaceutical
  81. Reykjavik: Icelandic Research Council
  82. Icelandic University Hospital
  83. Tartu: Estonian Science Foundation
  84. Turin: ASL 4 Regione Piemonte (Italy)
  85. AO CTO/ICORMA Regione Piemonte (Italy)
  86. Ministero dell'Universita e della Ricerca Scientifica (Italy)
  87. Glaxo Wellcome spa (Verona, Italy)
  88. Umea: Swedish Heart Lung Foundation
  89. Swedish Cancer & Allergy Foundation
  90. Uppsala: Swedish Heart Lung Foundation
  91. Verona: University of Verona
  92. Glaxo-SmithKline Italy

Ask authors/readers for more resources

Background: Rhinitis is an increasingly common condition with a heavy health care burden, but relatively little is known about its risk factors. Objective: To examine the association between early-life factors and the development of rhinitis in the European Community Respiratory Health Study (ECRHS). Methods: In 1992-1994, community-based samples of 20-44-year-old people were recruited from 48 centers in 22 countries. On average, 8.9 years later, 28 centers reinvestigated their samples. Onset of rhinitis was reported by 8486 participants in interviewer-led questionnaires. Cox regression was used to assess independent predictors of rhinitis at ages <= 5, 6-10, 11-20, and >= 21 years. Results: The crude lifelong incidence of rhinitis was 7.00/1000/year (men) and 7.95/1000/year (women) (P = .002). Women developed less rhinitis in later childhood (hazard ratios [HR], 0.63; 95% CI, 0.47-0.85) and more rhinitis in adulthood (HR, 1.36; 95% CI, 1.11-1.66) than did men. In atopic subjects, siblings were associated with lower risk of rhinitis throughout life (pooled HR, 0.94; 95% CI, 0.91-0.98 per 1 sibling). Early contact with children in the family or day care was associated with less incidence of rhinitis, predominantly before age 5 years (HR, 0.84; 95% CI, 0.72-0.99). Early childhood pets or growing up on a farm was associated with less incidence of rhinitis in adolescence (HR, 0.50; 95% CI, 0.37-0.68). Combining these factors showed evidence of a dose-response relationship (trend P = .0001). Conclusions: Gender is a strong risk factor for rhinitis, with age patterns varying according to atopic status. Protective effects of early contact with children and animals were suggested for incident rhinitis, with risk patterns varying by age window and atopic status. (J Allergy Clin Immunol 2011;128:816-23.)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available